ALIM — Alimera Sciences Share News
0.000.00%
Last trade - 00:00- $301.29m
- $360.44m
- $80.75m
Brief: Alimera Announces Pricing, Reimbursement Of Uveitis Indication Granted For Iluvien In France
Brief: Alimera Announces Approval And Pricing Granted For Iluvien® For Uveitis In Italy
Brief: Phase Iii Clinical Study Ind Accepted In China For Alimera’S Fluocinolone Acetonide Intravitreal Implant
Brief: Caligan Partners Lp Reports 5.9% Stake In Alimera Sciences As Of May 19, 2022 - SEC Filing
Alimera Sciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Alimera Sciences Reports First Quarter 2022 Results
Alimera Sciences Inc expected to post a loss of 69 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Biodelivery Sciences International, Foot Locker, Universal Health Services
U.S. RESEARCH ROUNDUP-Beigene, Foot Locker, Universal Health Services
Alimera Sciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Alimera Sciences Reports Fourth Quarter And FY 2021 Results
Brief: Alimera Sciences- Phase 4 Paladin Study With Iluvien® Published In Peer-Reviewed Journal Ophthalmology
Alimera Sciences Inc expected to post a loss of 42 cents a share - Earnings Preview
Alimera Sciences Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Alimera Sciences Announces Launch Of Iluvien For Uveitis In Spain
Alimera Sciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Alimera Sciences Posts Q3 Loss Per Share Of $0.60
Alimera Sciences Inc expected to post a loss of 52 cents a share - Earnings Preview
Alimera Sciences Inc expected to post a loss of 52 cents a share - Earnings Preview